HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
Eli Lilly is reducing its $2.67 billion investment in Germany's weight-loss syringe production due to new cost-cutting laws, and Boehringer Ingelheim is cutting $1 billion in German investments amid sector uncertainty. U.S. FDA Acting Commissioner Kyle Diamantas is engaging rare disease groups to address concerns raised by his predecessor's policies.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
- STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
- Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
- STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more